Japanese drugmaker Eisai and US-based Biogen have been working together on advancing research in the space of Alzheimer’s for nearly a decade. Finally, the FDA, granted the fruits of that labor, Leqembi, its blessing for intravenous use. This marks the first approved treatment that can slow the progression of Alzheimer’s.

  • S_204@lemm.ee
    link
    fedilink
    English
    arrow-up
    14
    ·
    1 year ago

    I wonder how this works in comparison to the RTMS therapy being used to slow/halt progression out of Canada?

    Either way, it’s great to see advancements on this front. The fake data debacle the other yeas was pretty disheartening.

    • thorbot@lemmy.worldOP
      link
      fedilink
      English
      arrow-up
      9
      ·
      1 year ago

      Yeah, any news like this is heartening but I always take it with a large grain of salt. I’ve got family member affected by Alzheimer’s so it really hits home.